Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01574703 · ClinicalTrials.gov registry record · Phase 4
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 4,595
- Enrollment target
NCT01574703 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 4,595 participants.
The verdict
NCT01574703, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4,595 participants
- Enrollment target
Study Summary
Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data collection.
Interventions
- DRUG placebo
- DRUG Nicotine Replacement Therapy Patch
- DRUG bupropion hydrochloride
- DRUG varenicline tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,595 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01574703
The ClinicalTrials.gov registry entry for NCT01574703 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 4,595 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT01574703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01574703 about?
NCT01574703 is a clinical study titled "Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.". Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data collection.
What is the current status of trial NCT01574703?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4,595 participants. The study started on 2012-05. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01574703?
The interventions under investigation include: placebo (DRUG), Nicotine Replacement Therapy Patch (DRUG), bupropion hydrochloride (DRUG), varenicline tartrate (DRUG).
Who is sponsoring clinical trial NCT01574703?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.